Correction: Combination treatment with rucaparib (Rubraca) and MDM2 inhibitors, Nutlin-3 and RG7388, has synergistic and dose reduction potential in ovarian cancer

Oncotarget. 2024 Feb 22:15:142. doi: 10.18632/oncotarget.28523.
No abstract available

Publication types

  • Published Erratum